Empaveli Prices, Coupons, Copay Cards & Patient Assistance
Empaveli (pegcetacoplan) is a member of the selective immunosuppressants drug class and is commonly used for Paroxysmal Nocturnal Hemoglobinuria.
The cost for Empaveli (1080 mg/20 mL) subcutaneous solution is around $5,197 for a supply of 20 milliliters, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Empaveli is available as a brand name drug only, a generic version is not yet available. View generic Empaveli availability for more details.
Empaveli prices
Subcutaneous Solution
1080 mg/20 mL
Empaveli subcutaneous solution
from $5,197.12
for 20 milliliters
| Quantity | Per unit | Price |
|---|---|---|
| 20 milliliters | $259.86 | $5,197.12 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Drugs.com Printable Discount Card
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Print Free Discount CardNote: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.
Empaveli Coupons, Copay Cards and Rebates
Empaveli offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
Empaveli Apellis Co-Pay Program
Eligible commercially insured patients may receive financial assistance to help cover co-pay and co-insurance costs.
- Applies to:
- Empaveli
- Number of uses:
- Per prescription until program expires
Form more information phone: 866-692-7527 or Visit website
Empaveli Apellis Bridge Program
Eligible commercially insured patients may receive a temporary supply of medication if experiencing a delay or change in insurance; for additional information contact the program 866-692-7527.
- Applies to:
- Empaveli
- Number of uses:
- Temporary Assistance
Form more information phone: 866-692-7527 or Visit website
Empaveli Trial Offer
Eligible insured patients may receive 8 weeks of medication at no cost.
- Applies to:
- Empaveli
- Number of uses:
- One-time offer
Form more information phone: 866-692-7527 or Visit website
Patient Assistance & Copay Programs for Empaveli
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: Patient Access Network Foundation (PAN)
Eligibility requirements:- *See Additional Information section below
- Between 400-500% of FPL
- FDA Approved Diagnosis - See Program Website for Details
- Must reside and receive treatment in US
- *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
- Empaveli (pegcetacoplan) Injection; Subcutaneous
More information please phone: 866-316-7263 Visit Website
Provider: ApellisAssist: Empaveli
Eligibility requirements:- Determined case by case
- Based on FPL
- FDA-approved diagnosis
- Must be residing in the US or US territory
- Prescribing Physician, Healthcare Facilities, Pharmacies and Patients must enroll into the Risk Evaluation and Mitigation Strategy (REMS) Program prior to initiating the patient on treatment with (Empaveli). Co-payment assistance, patient support, and patient assistance programs are available for eligible patients. This program may provide a Bridge Program for eligible patients who experience a delay, temporary loss, or change in coverage. Contact program for details. Please visit www.empaveli.com or call (866) 692-7527 for more information.
- Empaveli (pegcetacoplan) Injection; Subcutaneous
More information please phone: 866-692-7527 Visit Website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
See also:
Fabhalta
Fabhalta is used to treat paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A ...
Soliris
Soliris infusion is used to treat paroxysmal nocturnal hemoglobinuria (PNH) or neuromyelitis optica ...
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Voydeya
Voydeya (danicopan) is an oral complement factor D inhibitor that may be used to treat ...
Bkemv
Bkemv (eculizumab-aeeb) is an interchangeable biosimilar to Soliris which may be used to treat ...
Epysqli
Epysqli (eculizumab-aagh), a biosimilar to Soliris, targets the complement system to treat ...
Iptacopan
Iptacopan is used to treat paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A ...
Ravulizumab
Ravulizumab-cwvz is used to treat myasthenia gravis (gMG), hemolytic uremic syndrome (aHUS) ...
Eculizumab
Eculizumab (brand names Soliris, Bkemv, and Epysqli) is used to treat paroxysmal nocturnal ...
More about Empaveli (pegcetacoplan)
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: selective immunosuppressants
- Breastfeeding
- En español
